Trial Profile
Effective and safe examination of Luseogliflozin for patients with fatty liver merger type II diabetes mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2019
Price :
$35
*
At a glance
- Drugs Luseogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LEAD
- 01 Jan 2019 Primary endpoint (Rate of change of fat ratio in the liver) has been met as per results published in the Hepatology Research
- 01 Jan 2019 Primary endpoint (Change in HbA1c) has been met as per results published in the Hepatology Research
- 01 Jan 2019 Results published in the Hepatology Research